Long-acting GLP-1 drug TE-8105, developed by Taiwan biotech Immunwork, confirmed a five-day plasma half-life in first-in-human trials using a dual fatty acid bundle approach not used by any approved ...

The drugmaker said it would accept requests for early access to its experimental drug for some adults with severe obesity.

Incretin-based medications lower high-sensitivity C-reactive protein levels among adults with a range of cardiometabolic ...

Medicare patients are getting access to GLP-1s for obesity through the Bridge program. But questions linger regarding ...